美国胃肠病学会临床实践更新:美国胃癌风险增高人群的筛查与监测专家综述
该专家综述由美国胃肠病学会临床实践更新委员会委托,基于文献回顾与专家意见提出14条最佳实践建议,涉及美国胃癌高危人群识别、幽门螺杆菌根除、内镜筛查与监测、萎缩性胃炎和肠上皮化生的活检分期,以及异型增生和早期胃癌的内镜处理。建议未进行系统评价,故不附带正式的证据质量或推荐强度评级。
要点
- 美国存在可识别胃癌高危人群,包括高发地区第一代移民、一级亲属胃癌家族史者及特定遗传性综合征者,应考虑筛查。
- 内镜是风险增高人群筛查或监测的最佳检查,可直观分期黏膜、活检行组织学分期以进行风险分层。
- 高质量上消化道内镜应使用高清白光内镜联合图像增强、黏膜清洁、充分注气、足够观察时间、拍照记录及系统活检方案。
核心结论
- 美国特定高危人群可通过幽门螺杆菌根除实现胃癌一级预防,并通过癌前病变的内镜筛查和监测实现二级预防。
- 该专家综述提供14条最佳实践建议,用于美国当前临床实践背景下胃癌的一级和二级预防。
研究设计与样本
- 美国胃肠病学会临床实践更新委员会及理事会委托并批准,经内部同行评议和Gastroenterology标准外部同行评议。
- 建议来自已发表文献回顾和专家意见;未进行系统评价,故建议不附带正式的证据质量或推荐强度评级。
主要发现
- 建议1:美国存在可识别胃癌高危人群,包括高发地区第一代移民、可能其他非白种族裔群体、一级亲属胃癌家族史者及特定遗传性胃肠息肉病或遗传性癌症综合征者。
- 建议2:内镜是风险增高人群筛查或监测的最佳检查,可直观分期黏膜、识别可疑肿瘤区域并活检行组织学检查和黏膜分期。
- 建议3:高质量上消化道内镜应使用高清白光内镜联合图像增强、胃黏膜清洁、充分注气、足够观察时间、拍照记录及适当时系统活检方案。
- 建议4:幽门螺杆菌根除是必要的,作为内镜筛查和监测的辅助用于胃癌一级和二级预防;对风险增高者应考虑机会性幽门螺杆菌筛查。
- 建议4:对幽门螺杆菌阳性者的成年家庭成员也应考虑幽门螺杆菌筛查(即「家庭为基础检测」)。
关键数值与推荐
- 建议5:怀疑胃萎缩伴或不伴肠上皮化生者,应按系统方案(如更新悉尼系统)活检,至少取5块活检,胃窦/角切迹和胃体标本分装于单独标记的容器。
- 建议6:胃肠上皮化生和异型增生可经内镜检测,但内镜医师不熟悉特征性视觉表现时常漏诊;人工智能工具有望检测早期胃肿瘤,但数据太初步,不推荐常规使用。
- 建议7:内镜医师应与当地病理医师合作,对萎缩性胃炎伴或不伴化生达成组织学风险分层参数记录共识,至少记录幽门螺杆菌感染有无、萎缩和/或化生严重程度及胃肠上皮化生组织学亚型。
- 建议9:严重萎缩性胃炎和/或多灶性或不完全性胃肠上皮化生者可能从内镜监测获益,尤其有其他胃癌危险因素(如家族史)者;应考虑每3年监测一次,但间隔未明确定义。
- 建议13:萎缩性胃炎患者的I型胃类癌通常惰性,尤其<1 cm;内镜医师可考虑切除<1 cm的胃类癌,应内镜切除1-2 cm病变;>2 cm者应行横断面成像并转诊手术切除。
临床怎么用
- 建议8:风险增高者初次筛查内镜未发现萎缩、胃肠上皮化生或肿瘤时,继续筛查决策应基于个体危险因素和偏好;有胃癌家族史或多个危险因素者应考虑持续筛查,最佳筛查间隔未明确定义。
- 建议10:所有异型增生应由有经验的胃肠病理医师确认,可见或不可见异型增生患者应转诊至擅长胃肿瘤诊治的内镜医师或中心;不确定或低级别异型增生伴幽门螺杆菌感染者应治疗并确认根除,随后由有经验内镜医师重复内镜和活检。
- 建议11:疑似高级别异型增生或早期胃癌者应行内镜黏膜下剥离术,目标为整块R0切除以行准确病理分期并达治愈意图;活动性幽门螺杆菌感染根除必要,但不应延迟内镜干预;应在有内镜和病理专长的中心进行。
- 建议12:成功切除胃异型增生或胃癌者需持续内镜监测,已有建议监测间隔,但需额外数据完善监测建议,尤其在美国。
- 建议14:一般仅适合内镜或可能手术治疗者应筛查胃癌并继续监测癌前胃病变。
局限性
- 未进行系统评价,最佳实践建议不附带正式的证据质量或推荐强度评级。
- 人工智能工具检测早期胃肿瘤的数据太初步,不推荐常规使用。
- 最佳筛查间隔未明确定义。
- 内镜监测间隔未明确定义。
- 需额外数据完善监测建议,尤其在美国。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DESCRIPTION: Gastric cancer (GC) is a leading cause of preventable cancer and mortality in certain US populations. The most impactful way to reduce GC mortality is via primary prevention, namely Helicobacter pylori eradication, and secondary prevention, namely endoscopic screening and surveillance of precancerous conditions, such as gastric intestinal metaplasia (GIM). An emerging body of evidence supports the possible impact of these strategies on GC incidence and mortality in identifiable high-risk populations in the United States. Accordingly, the primary objective of this American Gastroenterological Association (AGA) Clinical Practice Update (CPU) Expert Review is to provide best practice advice for primary and secondary prevention of GC in the context of current clinical practice and evidence in the United States. METHODS: This CPU Expert Review was commissioned and approved by the AGA Institute CPU Committee and the AGA Governing Board to provide timely guidance on a topic of high clinical importance to the AGA membership, and underwent internal peer review by the CPU Committee and external peer review through standard procedures of Gastroenterology. These best practice advice statements were drawn from a review of the published literature and expert opinion. Because systematic reviews were not performed, these best practice advice statements do not carry formal ratings regarding the quality of evidence or strength of the presented considerations. Best Practice Advice Statements BEST PRACTICE ADVICE 1: There are identifiable high-risk groups in the United States who should be considered for GC screening. These include first-generation immigrants from high-incidence GC regions and possibly other non-White racial and ethnic groups, those with a family history of GC in a first-degree relative, and individuals with certain hereditary gastrointestinal polyposis or hereditary cancer syndromes. BEST PRACTICE ADVICE 2: Endoscopy is the best test for screening or surveillance in individuals at increased risk for GC. Endoscopy enables direct visualization to endoscopically stage the mucosa and identify areas concerning for neoplasia, as well as enables biopsies for further histologic examination and mucosal staging. Both endoscopic and histologic staging are key for risk stratification and determining whether ongoing surveillance is indicated and at what interval. BEST PRACTICE ADVICE 3: High-quality upper endoscopy for the detection of premalignant and malignant gastric lesions should include the use of a high-definition white-light endoscopy system with image enhancement, gastric mucosal cleansing, and insufflation to achieve optimal mucosal visualization, in addition to adequate visual inspection time, photodocumentation, and use of a systematic biopsy protocol for mucosal staging when appropriate. BEST PRACTICE ADVICE 4: H pylori eradication is essential and serves as an adjunct to endoscopic screening and surveillance for primary and secondary prevention of GC. Opportunistic screening for H pylori infection should be considered in individuals deemed to be at increased risk for GC (refer to Best Practice Advice 1). Screening for H pylori infection in adult household members of individuals who test positive for H pylori (so-called "familial-based testing") should also be considered. BEST PRACTICE ADVICE 5: In individuals with suspected gastric atrophy with or without intestinal metaplasia, gastric biopsies should be obtained according to a systematic protocol (eg, updated Sydney System) to enable histologic confirmation and staging. A minimum of 5 total biopsies should be obtained, with samples from the antrum/incisura and corpus placed in separately labeled jars (eg, jar 1, "antrum/incisura" and jar 2, "corpus"). Any suspicious areas should be described and biopsied separately. BEST PRACTICE ADVICE 6: GIM and dysplasia are endoscopically detectable. However, these findings often go undiagnosed when endoscopists are unfamiliar with the characteristic visual features; accordingly, there is an unmet need for improved training, especially in the United States. Artificial intelligence tools appear promising for the detection of early gastric neoplasia in the adequately visualized stomach, but data are too preliminary to recommend routine use. BEST PRACTICE ADVICE 7: Endoscopists should work with their local pathologists to achieve consensus for consistent documentation of histologic risk-stratification parameters when atrophic gastritis with or without metaplasia is diagnosed. At a minimum, the presence or absence of H pylori infection, severity of atrophy and/or metaplasia, and histologic subtyping of GIM, if applicable, should be documented to inform clinical decision making. BEST PRACTICE ADVICE 8: If the index screening endoscopy performed in an individual at increased risk for GC (refer to Best Practice Advice 1) does not identify atrophy, GIM, or neoplasia, then the decision to continue screening should be based on that individual's risk factors and preferences. If the individual has a family history of GC or multiple risk factors for GC, then ongoing screening should be considered. The optimal screening intervals in such scenarios are not well defined. BEST PRACTICE ADVICE 9: Endoscopists should ensure that all individuals with confirmed gastric atrophy with or without GIM undergo risk stratification. Individuals with severe atrophic gastritis and/or multifocal or incomplete GIM are likely to benefit from endoscopic surveillance, particularly if they have other risk factors for GC (eg, family history). Endoscopic surveillance should be considered every 3 years; however, intervals are not well defined and shorter intervals may be advisable in those with multiple risk factors, such as severe GIM that is anatomically extensive. BEST PRACTICE ADVICE 10: Indefinite and low-grade dysplasia can be difficult to reproducibly identify by endoscopy and accurately diagnose on histopathology. Accordingly, all dysplasia should be confirmed by an experienced gastrointestinal pathologist, and clinicians should refer patients with visible or nonvisible dysplasia to an endoscopist or center with expertise in the diagnosis and management of gastric neoplasia. Individuals with indefinite or low-grade dysplasia who are infected with H pylori should be treated and have eradication confirmed, followed by repeat endoscopy and biopsies by an experienced endoscopist, as visual and histologic discernment may improve once inflammation subsides. BEST PRACTICE ADVICE 11: Individuals with suspected high-grade dysplasia or early GC should undergo endoscopic submucosal dissection with the goal of en bloc, R0 resection to enable accurate pathologic staging with curative intent. Eradication of active H pylori infection is essential, but should not delay endoscopic intervention. Endoscopic submucosal dissection should be performed at a center with endoscopic and pathologic expertise. BEST PRACTICE ADVICE 12: Individuals with a history of successfully resected gastric dysplasia or cancer require ongoing endoscopic surveillance. Suggested surveillance intervals exist, but additional data are required to refine surveillance recommendations, particularly in the United States. BEST PRACTICE ADVICE 13: Type I gastric carcinoids in individuals with atrophic gastritis are typically indolent, especially if <1 cm. Endoscopists may consider resecting gastric carcinoids <1 cm and should endoscopically resect lesions measuring 1-2 cm. Individuals with type I gastric carcinoids >2 cm should undergo cross-sectional imaging and be referred for surgical resection, given the risk of metastasis. Individuals with type I gastric carcinoids should undergo surveillance, but the intervals are not well defined. BEST PRACTICE ADVICE 14: In general, only individuals who are fit for endoscopic or potentially surgical treatment should be screened for GC and continued surveillance of premalignant gastric conditions. If a person is no longer fit for endoscopic or surgical treatment, then screening and surveillance should be stopped. BEST PRACTICE ADVICE 15: To achieve health equity, a personalized approach should be taken to assess an individual's risk for GC to determine whether screening and surveillance should be pursued. In conjunction, modifiable risk factors for GC should be distinctly addressed, as most of these risk factors disproportionately impact people at high risk for GC and represent health care disparities.
引用
- Shah SC, Wang AY, Wallace MB, et al. AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer in the United States: Expert Review. Gastroenterology. 2024. PMID: 39718517. doi:10.1053/j.gastro.2024.11.001
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。